HomeTrialNCT06961968
🔬NCT06961968Phase 3RECRUITING

Randomized Withdrawal Study in Patients With Schizophrenia

Study Summary

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment400 participants
Primary Completion
Lead SponsorVanda Pharmaceuticals
Data Retrieved2026-04-11 04:31:05.188713+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.